From the Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, University of Kentucky Markey Cancer Center, Lexington, Kentucky; Applied Clinical Intelligence, Bala Cynwyd, Pennsylvania; and the Department of Pathology, Center for Biomarker Discovery, Johns Hopkins Medical Institutions, Baltimore, Maryland.
See related article on page 1289.
For a list of OVA1 trial sites and each primary investigator specialty, see the Appendix online at https://links.lww.com/AOG/A243.
Funded by Vermillion Inc., Austin, Texas.
Data from this article were presented at the 41st Annual Meeting on Women's Cancer, the Society of Gynecologic Oncologists, March 14–17, 2010, San Francisco, California, and at the 42nd Annual Meeting on Women's Cancer, the Society of Gynecologic Oncologists, March 6–9, 2011, Orlando, Florida.
Corresponding author: Rachel Ware Miller, MD, Assistant Professor of Gynecologic Oncology, University of Kentucky Markey Cancer Center, 800 Rose Street, Lexington, KY 40536-0298; e-mail: [email protected].
Financial Disclosure Dr. Frederick Ueland was the principle investigator for the OVA1 trial and became a member of Vermillion's speaker's bureau in January 2011. He also has received honoraria as a speaker for Vermillion. Dr. Alan Smith is an independent statistician hired by Vermillion for data analysis. Dr. Zhen Zhang is an employee of the Johns Hopkins Center for Biomarker Discovery, which has a sponsored research grant from Vermillion. He is entitled to royalty payment through a license agreement between Johns Hopkins University and Vermillion. The other authors did not report any potential conflicts of interest.